ESMO Open

Article	Citations
Editorial Board	242
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	213
Editorial Board	139
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	138
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	132
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer	126
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	121
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	120
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	100
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	100
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	99
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	97
ESMO	95
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	89
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	87
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	87
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	85
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	83
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	82
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	79
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	79
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	75
Editorial Board	75
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	74
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	67

100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	66
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	66
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	66
Editorial Board	65
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	65
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	63
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	63
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	62
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	60
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	59
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	58
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	55
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	53
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	53
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	52
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	51
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	51
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	49
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	48
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	48
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	48
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	48
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	47
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	47
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	46
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	46
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	46
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	46
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	45
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	45
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	45
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	45
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	44
Table of Contents	44
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	43
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	43
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	43
Table of Contents	43
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	42
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	42
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	42
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	41
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	41
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	40
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	39
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	39
Table of Contents	38
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	38
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	37
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	37

144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	37
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	37
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	37
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	37
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	36
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	36
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	36
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	35
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	35
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study	35
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	35
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial	35
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	34
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	34
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN	33
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	33
Refining patient selection for breast cancer immunotherapy: beyond PD-L1	33
Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores	33
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	32
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities	32
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	32
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	32
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	32
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	31
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	31
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	31
225P The impact of predictive genomic testing in Ireland: Financial and resource implications for healthcare institutions and patients	30
307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial	30
238P Comparing the benefit-risk profiles of emerging treatments in early breast cancer (eBC) using the ESMO MCBS and the ASCO value framework	30
334P The nationwide Advanced Breast Cancer - Patient Care Initiative (ABC-PCI): A medical oncologist-led survey on quality of life in Chinese patients with metastatic triple-negative breast cancer	29
393P Treatment outcomes and toxicity of palbociclib in metastatic hormone receptor (HR)-positive HER2 -ve breast cancer patients: Real-life palbociclib outcome in Omani patients	29
90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)	29
222P Hemoglobin A1c screening for patients with early breast cancer treated with adjuvant endocrine therapy	29
357P BRCA genetic testing implementation and the impact of BRCA pathogenic variant status on clinical outcomes in HER2-negative metastatic and recurrent breast cancer in Japan	29
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA	29
438P Antidepressants/anxiolytics and breast cancer treatment: The case of drug-drug interactions	29
420P Physicians’ knowledge, practice and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: Results of the ABC6 and ABC7 survey	29
43eP Is age a risk factor for locally advanced cervical cancer persistence?	28
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation	28
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	28
148P AI driven adjuvant therapy: Predicting pCR from radiological data in patients receiving incomplete NACT for LABC	28
72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICC	28
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies	28
71P Relapse rate in patients avoiding adjuvant chemotherapy based on Oncotype DX score: Real-world data from three UK centres	28
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	27
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	27
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	27
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	27
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy	27
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	26
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	26
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	26
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	26
Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: developme	26
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	26
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	26
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	26
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study	25
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	25
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India	25
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	25
23P Anti-tumor activity of novel Globo-H targeting CAR T cells in cholangiocarcinoma model	25
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis	25
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	25
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review	25
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	24
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	24
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study	24
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	24
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	24
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	24
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis	24
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	24
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	24
Collagen signature adds prognostically significant information to staging for breast cancer	24
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	23
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer	23
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer	23
44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial	23
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis	23

268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation	23
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	23
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	23
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	23
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes	23
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	22
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	22
11P Conization before radical hysterectomy in early cervical cancer: A Korean multi-center study	22
45P Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence	22
14P Unravelling the immune landscape of non-epithelial ovarian cancer	22
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs	22
117P Merkel cell carcinoma: Epidemiological pattern in the United States, a SEER based study	21
29P First-line of camrelizumab, apatinib mesylate and chemotherapy for advanced high-grade neuroendocrine tumors (NETS): A single center, single arm, exploratory study	21
53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation	21
17P Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma	21
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	21
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	20
Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-	20
154P Alternative splicing in non-small cell lung cancer evolution	20
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	20
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study	20
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	20
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	19
Editorial Board	19
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	19
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	19
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	19
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	19
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	19
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	19
54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment	19
224P Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibito	19
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	19
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	19
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	19
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	19
83P Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin	18
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer	18
139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis	18
90P Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients? A real-life study	18
PP108 Is it possible to avoid seroma after mastectomy and axillary lymph node dissection using microporous polysaccharide hemispheres (AristaTM)?	18
108P Establishing a multi-modal tissue preparation and imaging workflow to study heterogeneity in neuroblastoma tumors	18
96P Age-adjusted trends and survival analysis of alveolar soft part sarcoma	18
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	18
161P DESCARTES trial: De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy	18
PP067 Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients	18
OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC	18
18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate	18
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	18
252P Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project	18
18P PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response	18
263P Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: A study of the French	18
PP215 Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the type of EGFR activating mutations and agents in non-small cell lung cancer (NSCLC): A real-world study	18
14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status	17
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	17
58P Evaluating the impact of WGTS in routine diagnostics of bone and soft tissue tumors	17
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical O	17
58P The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma	17
PP065 In silico genetic polymorphisms analysis of GSTP1 and their effect on platinum compound and antituberculosis drugs co-medication in lung cancer patients with tuberculosis comorbidity	17
PP499 3-weekly daratumumab-based quadruplet induction regimen is highly effective in newly diagnosed multiple myeloma	17
142P Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis	17
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	17
114P Effects of chemotherapy on TREG lymphocytes in early breast cancer	17
80P Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs	17
PP064 MicroRNA 200c-3p targeting CDH1 gene polymorphism towards risk susceptibility of prostate cancer in North Indian population	17
79P Real-world comparative analysis of liposomal doxorubicin and paclitaxel in first-line treatment of Kaposi sarcoma: A retrospective study in Brazil	17
153P BRAF variants and therapy outcomes in melanoma	17
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma	17
258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or met	17
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer	16
53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer	16
136P Vascular endothelial growth factor A (VEGF-A) expressions in invasive breast cancer and its association with lymph node metastasis and histopathologic features	16
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phas	16
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer	16
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy	16
189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial	16
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	16
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece	16
56P Neoadjuvant treatment with sequential letrozole and exemestane in postmenopausal patients with HR-positive, HER-2 negative breast cancer: Clinical and biomarker outcomes from the NEOLETEXE trial	16
134P Gene alterations in Mongolian breast cancer patients	16
120P Genetic associations of plasma proteins and breast cancer: Potential therapeutic drug candidates	15
24P The role of radiotherapy for intermediate-risk in early-stage cervical cancer post-radical hysterectomy: A meta-analysis	15
37eP Local control with chemoradiotherapy in patients with metastatic cervical cancer	15
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)	15
398P Evaluation of trastuzumab deruxtecan for metastatic HER2+ breast cancer: A meta-analysis	15
439P The bio-psycho-social predictors of mental health among women with breast cancer	15
487P Health care provider’s adherence to clinical practice guidelines in diagnosing and staging breast cancer: An observational study	15
430P Analysis of quality of life in a group of very long-term early stage breast cancer survivors	15
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab	15
Imaging of extranodal extension: why is it important in head and neck cancer?	15
246P Four years of Oncotype DX test in clinical practice: the experience of the breast unit of University Hospital of Parma	15
229P Risk of recurrence and overall survival in Stage II and III ER+/HER2- early breast cancer: A population-based registry study in Sweden	15
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial	15
Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors	15
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	15